Validating disease progression models using real world data
Disease models which use ‘real world data’ from existing population cohorts can be used to improve efficiency of drug treatment strategies.
The 'Real world Outcomes across the Alzheimer's Disease spectrum for better care initiative' – ROADMAP – was created to facilitate the open collaboration among a variety of stakeholders to efficiently use real world evidence (RWE) for the benefit of patients with Alzheimer’s disease and their carers. The objective of the study is to validate natural disease progression models in people with Alzheimer's disease.
The impact of this research is to build a disease progression model that can be used for the health economic evaluation of the efficiency of different treatment pathways.